IRESite record type: plasmid_with_promoter_and_putative_IRES_translationally_characterized
The shape of the nucleic acid molecule translated: linear
The quality of the mRNA/+RNA sequence: end-to-end_full-length_mRNA
The mRNA/+RNA description:
In vitro T3 run-off transcript containing 5' region of EMCV-R containing the IRES (-574 to -1) plus the first
8 nucleotides from the viral polyprotein cloned upstream of the luciferase reporter RNA with a poly(A) tail.
The mRNA/+RNA sequence represented in the +DNA notation:
Credibility of mRNA sequence: end-to-end_sequence_completely_same_as_in_the_experiment
The name of the promoter used to express this mRNA: T3
Description of the plasmid (facultative for promoter-less plasmid records): Plasmid containing part of EMCV-R 5' UTR (-574 to -1) plus the first 8 nucleotides from the viral polyprotein
(+1 to +8) and firefly luciferase coding region (luc version of the luciferase gene) with the poly(A) tract.
The in vivo produced transcripts are heterogeneous (due to any of promoter?/splicing?/cleavage?/breakage?): not tested
The in vivo produced heterogeneous transcripts occur due to alternative splicing: not tested
A promoter reported in cDNA corresponding to IRES sequence: not tested
The abbreviated name of the donor gene or virus from which this IRES was excised and inserted into the plasmid: EMCV-R
The translation method used to study IRES function: in vitro
The in vitro translation system: HeLa cell lysate
The organism used for translation:
The temperature (in degrees of Celsia): 37
The relative translation efficiency in % of this IRES: 100.000
Name of the plasmid used as the negative control. pT3Luc-pA
IRESite Id of the plasmid used as negative control. 347
The relative translation efficiency in % of the negative control: 0.050
The effect of 5'-cap analogs on translation: no
Rapamycin affects translation: not tested
Type of RNA subject to translation: exogenous_RNA_with_ApppG_cap_with_polyA_tail
Translation of EMCV.IRES-pA RNA is unaffected by increasing amounts of m7GpppG competitor (see Fig. 7D).
The translation of EMCV.IRES-pA RNA is about 2.5-fold higher efficient than the translation of the
polyadenylated counterpart EMCV.IRES RNA (see Fig. 6B).
Translational data are derived from Fig. 6B.